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Abstract
Background: Thyroperoxidase (TPO) is a membrane-bound protein essential for the production of thyroid hormones;
because of this, TPO expression may be impaired in selected thyroid diseases. The goal of this study is to analyze TPO
immune expression in differentiated thyroid cancer, and to determine whether TPO has any prognostic value.
Methods: A total of 139 patients who required surgery due to a thyroid nodule with signs or symptoms suspicious for
malignancy during their physical, ultrasound and/or cytology examination were consecutively selected for the study. A
study of TPO immunohistochemical expression was carried out on these patients using the MoAb47 monoclonal
antibody. In addition, cell proliferation marker Ki67 and tumor suppressor p53 were also measured for comparison.
Results: A total of 139 cases, 43 benign tumors, 42 papillary carcinomas, 38 follicular carcinomas, 8 undifferentiated
carcinomas, and 8 sporadic medullary carcinomas were analyzed. The relationship between TPO expression and
disease was statistically significant (p <0.001), and decreased with tumor dedifferentiation extent. Increased TPO
expression in benign lesions as compared to decreased expression in papillary carcinomas and undifferentiated tumors
is outstanding. Differences in TPO expression were observed in minimally invasive follicular carcinoma (MIFC)
compared to widely invasive follicular carcinoma (WIFC). TPO expression decreases in undifferentiated malignancies in
contrast with p53 and Ki67 expression, which increases in that setting. TPO, p53 and Ki67 expression was significantly
related to TNM stage (p <0.001). Survival rate was 72 % after a 20-year follow-up, and 100 % for subjects with higher
TPO expression.
Conclusions: TPO may be useful in confirming or ruling out benign diseases from differentiated thyroid carcinoma,
with the exception of low-risk carcinoma such as MIFC. It could be used as a prognostic factor for differentiated thyroid
cancer and patient follow-up, together with other markers.
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Background
Thyroperoxidase (TPO) is a membrane-bound protein
essential for thyroid hormone production, characteristic
of functional, normal thyroid cells. TPO expression is
considered a thyroid differentiation marker. Qualitative
and quantitative alterations in TPO activity, TPO mes-
senger ribonucleic acid (mRNA), and protein expression
can be related to thyroid changes and have been reported
in pathological thyroid tissues [1]. TPO content has been
shown to be significantly lower in thyroid malignancies as
compared to benign conditions and normal tissue [2];
also, a reduction in TPO activity and TPO mRNA of 55–
70 % is observed in differentiated thyroid carcinoma
(DTC) [1, 3]. Moreover, anaplastic tumors have non-
existent TPO expression. The biological meaning of this
abnormal TPO expression is unclear; however, a deregula-
tion of protein synthesis can be related. A progressive de-
crease in TPO levels, together with increased cell density,
suggests an association with proliferation.
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Molecular tests are emerging that measure different gene
and protein combinations that may differentiate benign lesions
from DTC [4–6]. Although these studies have shown good re-
sults and can be promising for the future, these techniques are
not readily available in every hospital. On the other hand,
immunohistochemistry techniques could be an easier option
to differentiate between benign thyroid lesions and DTC.
Many studies have described immunohistochemical
markers that improve the diagnosis of thyroid conditions
such as TPO on their own or, alternatively, associated with
other markers such as galectine-3, CK19, HBME-1, etc. De
Micco determined that anti-TPO antibody MoAb47 recog-
nized TPO expression in normal and benign thyroid tissues,
but only in 3 % of malignant tumors [7]. TPO gene and pro-
tein expression in thyroid carcinoma have been analyzed, in-
dicating low enzymatic activity [2], impaired solubility and
suppressed TPO mRNA expression [8]. Savin et al. studied
the value of TPO combined with galectine-3 in DTC, ob-
serving that TPO had an intense expression in normal or
hyperplasic thyroid tissue, and was down-regulated in
thyroid pathologies. They reported an inverse correlation
with known prognostic factors and TNM staging [9].
However, other reports have obtained the same TPO ex-
pression in both benign thyroid diseases and DTC [10].
This study analyzes the immunohistochemical expres-
sion of TPO (using MoAb-47) in both benign and malig-
nant lesions to establish the relationship between TPO
expression, histological type, differentiation degree, and
tumor growth. In malignancies, including both differen-
tiated and undifferentiated cancers; a comparative ana-
lysis of TPO with proliferation factor Ki67 and cell-cycle
suppressor protein p53 was carried out [11–13].
Methods
Patients with thyroid nodules and signs or symptoms suspi-
cious for malignancy during physical, ultrasound and/or cy-
tology examination who required surgery during the period
1972 to 1995 were consecutively selected for this study. The
ethical approval and informed consent of patients were ob-
tained (The institutional review board was approved by the
committe of the Hospital Universitario Insular de Gran
Canaria and the University of Las Palmas of Gran Canaria).
The institutional review board was approved by the committe
of the Hospital Universitario Insular de Gran Canaria and the
University of Las Palmas of Gran Canaria. Only 139 cases
were included as we had a limited number of monoclonal
antibodies available for the TPO immunohistochemical study.
Data was prospectively collected and patients were divided
into four groups according to their histological diagnosis: be-
nign cases, papillary thyroid carcinoma (PTC), follicular thy-
roid carcinoma (FTC), and a fourth group called “others”,
which included undifferentiated thyroid carcinomas and spor-
adic medullary carcinomas. Specific variants were included in
the study, such as the follicular variant of papillary carcinoma
and Hürthle cell carcinoma for the PTC group, clear cells and
insular pattern for the FTC group. Even though sporadic
medullary carcinomas are related to C-cells (and therefore
to calcitonin levels) they were not excluded, as we wanted
to evaluate TPO, p53 and ki67 expression.
Histological analysis
After gross examination, the specimens were fixed in
10 % formaldehyde and embedded in paraffin. Blocks
were cut using a Leica microtome into 4–5 micron sec-
tions, and then studied with several staining techniques
(Harris or Mayer hematoxylin, eosin, PAS).
Immunohistochemistry
The antibodies used for the immunohistochemical study in-
cluded MoAb-47 for TPO, DO-7 for p53, and Ki67 -MM1
against antigen Ki67.
Once obtained, histology blocks were placed in the
heater for twelve hours at 37 °C and then soaked in xilol
three times over 15 min, twice in absolute alcohol over
10 min, once over 5 min in 96 % alcohol, once in 70 %
alcohol, and lastly once time during 5 min in distilled
water. Afterwards, all slides were placed in a pressure
cooker with citrate buffer solution as a recovery anti-
genic system. A process to inhibit endogenous peroxid-
ase using 250 ml of 30 % hydrogen peroxide with 10 ml
of methanol during 10 min followed this. Antibody solu-
tions were prepared with the following dilutions: TPO
1:50, p53 1:50, and ki67 1:100; these were maintained at
a temperature of 4 °C during the staining process. Then
we started the incubation process without washing the
slides with the primary antibody during 1 h, with the sec-
ondary antibody during another hour, and with the avidin-
biotin-peroxidase complex during 30 min.
In the final stage, slides were washed in PBS for 15 min
with agitation, and subsequently developed with chromo-
genic substrate for 3 to 6 min away from direct light (diami-
nobenzidine [DAB] solution); then they were washed with
tap water for 5 min 3 times, and contrasted with Harris’ or
Mayer’s hematoxylin for 1 min; finally they were dehydrated
using a growing alcohol series (70 %, 96 %, and 100 % twice,
and xylol clearing solution twice), and eventually mounted
with coverslips using DPX).
Routine techniques such as Congo red under polarized
light and calcitonin immunohistochemistry were used
for sporadic medullary carcinomas.
Immunohistochemistry assessment
TPO expression was measured under a light micro-
scope, in terms of percentage of stained cells and stain
intensity, using different scores. For the percentage of
stained cells an Arabic number was given: 0, 1–10 %
stained cells = 1, 10–33 % = 2, 33–66 % = 3, >66 % = 4; and
for stain intensity: negative = 0, mild = 1, moderate = 2,
Caballero et al. Thyroid Research  (2015) 8:12 Page 2 of 9
intense = 3. Intensity and proportion of stained cells were
summed using the Vargas-Roig method [14] in order to
obtain a single result. Thus, a tumor with a total result of
0–2 was classified as negative, one with 3–4 as mild posi-
tive, one with 4–5 moderately positive, and one with 5–7
as intensely positive. One pathologist, who was blinded to
cytology results, was in charge of the immunohistochemi-
cal expression measurement. Separately, another patholo-
gist studied the surgical specimen and provided a final
histological diagnosis. The scoring was performed with
blinding to patient outcome.
Furthermore, mean, standard deviation, and 95 % con-
fidence interval values were found for each area, both re-
garding percentage and intensity. The morphological
aspects of immunostains were also described for the dif-
ferent pathologies. Overall survival was analyzed accord-
ing to TPO level and TNM stage, as well as disease-free
survival. Disease-free survival was considered for DTC
when there was no clinical evidence of tumor, no im-
aging evidence of tumor, and undetectable serum thyro-
globulin levels during TSH suppression and stimulation
in the absence of interfering antibodies. For medullary
thyroid carcinoma, calcitonin serum levels and carci-
noembryonic antigen (CEA) levels were tested every
6 months during the first year, and then annually with
an imaging procedure for control.
Statistical analysis
Data was analyzed using the SPSS v. 18.0 software. Stat-
istical techniques included Pearson’s squared chi test for
the study of association between categorical variables;
Student’s t-test in the comparison of means for normally
distributed numerical variables; Wilcoxon’s non-parametric
test in case of non-normality; a binary logistic regression
model to find parameter profiles and TPO, Ki67, and p53
values; and a Cox proportional hazard analysis for asses-
sing the effect of each prognostic factor on overall sur-
vival. A significance level of 5 % (p <0.05) was established
for all tests.
Results
This series includes a total of 139 cases, 43 benign and 96
malignant, classified in four groups. Table 1 summarizes
the histological diagnoses by group. The surgical proce-
dures performed included lobectomies, subtotal thyroid-
ectomies (this type of procedure was carried out in
patients from 1972 to 1995), and total thyroidectomies.
The immunohistochemical expression of TPO, p53
and Ki67 by disease is detailed in Figs. 1 and 2. TPO ex-
pression related to histological diagnosis was statistically
significant (p <0.001), with expression decreasing with
cellular dedifferentiation. TPO staining patterns were
also found in the different groups.












Papillary carcinoma Papillary Carcinoma 38
Follicular variant 4
Total 42
Follicular carcinoma Widely invasive 28
- Clear cells 2
- Hürthle cells 2
- Insular pattern 5
Minimally invasive 10
Total 38
Other Undifferentiated carcinoma 8
Sporadic medullary carcinoma 8
Total 16
Fig. 1 TPO immunohistochemical expression according to tumor
histology. TPO by groups showed an intense expression of TPO in
benign cases when compared to the rest of groups, decreasing
significantly in the papillary group, as well as in undifferentiated and
sporadic medullary tumors (group “others”), where it was mainly
negative. In the follicular group, TPO expression was variable, showing
positive TPO expression but not as much as in the benign cases
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Benign pathology
In multinodular hyperplasia TPO was consistently posi-
tive in the cytoplasm (TPO staining scores: 2.7–5.5),
with an irregular distribution highly intense in small fol-
licles with apical TPO concentrations (Fig. 3). Uninodu-
lar cases showed moderate to high immunostaining (3.9
to 6.0) in the cytoplasm, particularly in microfollicular
areas with cytoplasmic granules, as may be expected
from a benign disease. A direct association between TPO
intensity, presence of microfollicles, and localization in
areas near the capsule was found. In contrast, p53 and
Ki67 expression was mostly negative.
TPO expression was moderate to high in all adenomas
(mean 4.5), regularly distributed in the cytoplasm with a
marked apical predominance. In Hürthle-cell adenomas
low TPO positivity is characteristic both in central and
subcapsular follicles; positivity is only outstanding for
papillary growth patterns. The histological study of p53
was negative in all but two cases – microfollicular and
embryonic types. Ki67 expression had intermediate posi-
tivity (1.2 to 2.4) in normal follicular, microfollicular and
Hürthle-cell adenomas, with higher levels in a trabecular
adenoma.
Papillary thyroid carcinoma
TPO staining was usually poor to moderate (<3) in 81 %
of cases – higher TPO scores were only seen in four pa-
tients (3.6 and 6) – with positive expression in the apical
pole of cells in the cystic epithelium and negative ex-
pression in Psammoma bodies (Fig. 4b). In follicular var-
iants, negativity was seen in most fields except for focal
areas with a regular and patchy distribution.
Protein p53 had mild to moderate staining overall, and
Ki67 showed an equal distribution of mild, moderate
and negative staining.
Follicular thyroid carcinoma
TPO results revealed positivity with irregular expression
in most cases. Minimally invasive follicular cases (MIFC)
(3.5 and 4.9) showed greater TPO immunostaining as
compared to widely invasive follicular cases (WIFC) (1.4
and 2.9), with the presence of extensive, totally negative
areas in contrast to their neighboring lesion zones
(Fig. 4a). Five cases were totally negative. FTC showed
decreased TPO immunostaining, both in intensity and
percentage, when compared to hyperplasia and, to a
lesser extent, thyroid adenoma. These lesions had an
Fig. 2 p53 and ki67 levels by histological group. The figure at the
top shows p53 expression by group, with benign cases showing a
negative expression. Papillary and follicular carcinomas had a mild to
moderate positive expression, with increasing intensity in the
undifferentiated cases. In the figure at the bottom, ki67 showed an
intermediate positive expression in benign cases, with an equal
proportion of mild, moderate and negative cases in papillary
carcinomas, then dropping to scantly positive in follicular cases and
arising to intense positive in undifferentiated carcinomas
Fig. 3 Multinodular hyperplasia: Nodular hyperplasia showing
cytoplasmic TPO expression (TPO x20) – highly intense in small
follicles and apical areas
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irregular and cytoplasmic TPO stain, with mild and in-
tense areas. In MIFCs TPO expression was moderate to
intense in the cytoplasm and mild or negative in the nu-
clei; intracellular distribution was uniform from basal to
apical areas. The presence of TPO in infiltrating follicles,
including those protruding into the vascular lumen, is
interesting. In WIFCs, expression was usually poorer.
P53 was negative for most MIFCs and positive in three
Hürthle-cell carcinomas (1.5–3); WIFCs had scant posi-
tivity, and both clear-cell and insular-pattern lesions
were negative. Ki67 was scarcely positive in both MIFCs
and WIFCs (0.4 and 1.3), with insular variants being
moderately positive (1.4 and 3.7).
Others
Non-differentiated carcinoma
TPO was negative except in one case, which was consid-
ered follicular reclassified as anaplastic. P53 positivity
was generally intense (4 and 6.5), and Ki67 was positive
in all cases with variable intensity (0.4 and 5.8), with an-
aplastic variants being more intensely positive (Fig. 4c).
Sporadic medullary carcinoma
TPO was negative in most cases and moderate in three;
the presence of TPO in cytoplasmic vesicle-like deposits
was noteworthy (Fig. 4d). P53 immunostaining was
negative except for two cases where it was markedly
weak (0.2), and Ki67 was negative in four cases and mild
to moderate in the remaining four (2 y 4).
The cancer cohort was classified according to TNM
stage. Figure 5 illustrates the association between TPO
immunostaining and TNM stage, observing that TPO
decreases as TNM increases.
Follow-up was carried out on an outpatient basis by
the endocrinologist and the surgeon by way of physical
examination, yearly thyroglobulin levels, and ultrasounds
for suspected relapse. A maximum follow-up of 20 years
was carried out. Minimum and median follow-up was 5
Fig. 4 a Well-differentiated follicular carcinoma: TPO expression appears positive in normal thyroid cells and negative in tumor cells (TPO x20);
b Papillary carcinoma: positive TPO expression in the apical portion of epithelial cells and negative in Psammoma bodies (TPO x40); c Undifferentiated
carcinoma: negative TPO expression (TPO x40); d Medullary carcinoma: expression of TPO in cytoplasmic vesicles (TPO x20)
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and 15 years, respectively. A survival study was carried
out, limited to patients with cancer, according to total
TPO level (Fig. 6a) and TNM stage (Fig. 6b). Disease-
free survival related to TPO expression (Fig. 6c) and
TNM stage (Fig. 6d) was also analyzed.
According to TPO level, overall survival decreased in
negative cases compared to positive cases without reach-
ing statistical significance (p = 0.34). On the other hand,
survival decreased with higher TNM stages (p <0.001), as
patients in stage IV had a 20-year survival of 52 % (SD
0.18) compared to patients in stage III and II, who had a
20-year survival of 83 % (SD 0.15) and 90 % (SD 0.09), re-
spectively. We did not find any reason for the different
survival rates in stages II and III, as they are differentiated
by patient age and tumor size and localization.
Disease-free survival also decreased significantly in
cases with higher TNM stages (p <0.001). Patients in
stage I had a 95 % disease-free survival after a 20-year
follow-up. This rate dropped to 47 % for stage II, where
patients under the age of 45 are included without taking
into account tumor size or local or distant invasion.
Stage III had a 29 % disease-free survival, whereas for
stage IV all patients were ill at the end the observation
period.
Discussion
TPO is a membrane-bound protein essential in the pro-
duction of thyroid hormones. It catalyzes the iodination
and coupling of tyrosyl residues to thyroglobulin to form
thyroid hormones T3 and T4. TPO expression pattern
correlates with thyroid follicular cell function, both at
the cytoplasm and apical membrane compartments.
Quantitative and qualitative changes are related to hor-
mone biosynthesis abnormalities usually due to thyroid
disease. The biological meaning of abnormal TPO ex-
pression in thyroid tumors is unclear, but the progressive
decrease of TPO levels together with an increase in cell
density suggests it is correlated with proliferation [1–3].
Ki67 was used to study the proliferative activity of tu-
mors, which determines their aggressiveness, progression,
and metastatic potential. It is a monoclonal antibody that
binds an antigen present in proliferating cells, but absent
from quiescent cells [11]. On the other hand, gene p53 is
a suppressor gene that codes for a p53 protein that plays a
role in cell-cycle control, replication, and DNA repair.
Mutated p53 accumulates in the nucleus of tumor cells,
and is promptly identifiable using immunohistochemical
techniques [12, 13].
A huge variety of molecular tests are now available for
the measurement of prognostic factors in thyroid carcin-
oma. Weber [4] identified a 3-gene combination to differ-
entiate follicular adenomas from follicular carcinomas,
with 100 % sensitivity and 97 % specificity. Rosen [5] com-
pared gene expression in benign thyroid lesions versus
papillary carcinoma, and described a set of 6 genes that
predicted pathological diagnosis with 75 % sensitivity and
100 % specificity; Kroll [6] described fusion protein PAX8/
PPAR-γ as a marker to distinguish benign from malignant
follicular lesions. However, molecular techniques and gene
studies are costly and time-consuming procedures that
render their routine use difficult.
Our study’s approach is different. Using simpler methods,
such as immunohistochemistry, we analyzed TPO, p53 and
Ki67 expression with the purpose of assessing whether
TPO is useful as a prognostic marker by means of a long-
term survival study. We have not found any literature
describing a single study with such a long follow-up. The
relationship between TPO expression and disease was sta-
tistically significant (p <0.001) and decreased with tumor
dedifferentiation extent. We do not know exactly why
TPO is lost or increased according to tumor growth or de-
velopment, albeit we suspect that differentiation criteria
are involved. Increased TPO expression in benign lesions
as compared to PTC and undifferentiated tumors is
outstanding.
TPO increased in FTC to a lesser extent than in benign
lesions, with differences in TPO expression between
MIFC and WIFC being consistent with most reported
studies [7, 15–17]. However, others such as Savin et al.
among 47 cases of FTC observed an overall TPO expres-
sion of 78.7 % without correlation with degree of histo-
pathological aggressiveness, as TPO expression in WIFC
was not less reactive than in MIFC [9]. Microfollicular
Fig. 5 Relationship between TPO level and TNM stage: The figure
shows how TPO expression decreases when TNM increases in terms
of intensity, as in stage I more positive than negative cases are
found, and in stage II, III and IV more negative than positive cases
are observed
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adenomas and MIFCs show increased TPO levels, which
may reflect a failure of these invasive cells to lose function
and differentiation despite their neoplastic course.
In contrast, De Micco [7, 15] observed that immuno-
staining was irregular in adenomas, moderate in 40 % of
the remaining diseases, and negative in follicular carcin-
omas. This report does not include morphological criteria,
immunostaining differences across areas, cytoplasmic
localization, intensity assessment, or percentage per histo-
logical fields. Weber [4], in a series of 9 FTCs, found that
only one was negative, thus reporting high positivity levels
and a low sensitivity of TPO for this type of malignancy.
In another study, Weber analyzed the use of TPO and
galectine-3 separately for the diagnosis and prognosis of
thyroid cancer — also combining both markers — and ob-
tained with TPO staining a sensitivity of 39 % for any can-
cer, of 50 % for PTC, and of 11 % for FTC, which
increased with galectine-3 immunostaining to 82 %, 96 %
and 44 %, respectively [18]. Therefore, follicular cancer is
associated with abnormal TPO expression in studies, with
a decrease in TPO immunostaining in 80–95 % of follicu-
lar carcinomas.
The scarce TPO staining of PTC in our series is con-
sistent with other reports [15, 19, 20] that show strong
TPO suppression in papillary carcinomas. The negative
TPO expression found in undifferentiated carcinomas,
where cells lack their endocrine function, supports an
association between cell differentiation and TPO levels.
BRAFV600E mutation is one of the most common gen-
etic alterations in thyroid carcinogenesis. Its presence in
papillary carcinomas has been reported to be associated
with advanced stages [21] and poorer clinical outcome,
although this remains controversial. Romei et al. analyzed
the mRNA expression levels of TPO, among others, ac-
cording to the presence of BRAFV600E mutation [22]. They
observed a higher prevalence of the mutation in classical
PTC, rather than the follicular variant, and a significantly
lower mRNA expression of TPO (p <0.0001) in PTCs with
BRAFV600E mutation as compared to negative cases, sug-
gesting that BRAFV600E-mutated PTCs, although still well
Fig. 6 a Overall survival according to TPO level: overall survival decreases with TPO expression. b Overall survival according to TNM stage: Overall
survival decreased with TNM stage, with a 20-year survival of 90 %, 83 % and 52 % in stages II, III and IV, respectively. c Disease-free survival
according to TPO expression: d Disease-free survival according to TNM stage: The figure shows how disease-free survival (DFS) decreased with
TNM stages, with 95 % in stage I, 47 % in stage II, 29 % in stage III, and 0 % in stage IV
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differentiated, are losing the typical features of follicular
cells. Therefore, this mutation may be related to an early
dedifferentiation process rather than advanced PTC
stages. In this study we did not analyze TPO expression
according to this mutation; however, we are looking for-
ward to starting a new study in this respect.
TPO expression according to TNM stage shows that
TPO substantially decreases when TNM increases. The
comparison of mean TPO, Ki67 and p53 values was sta-
tistically significant (p <0.01), which corroborates that
the immunohistochemical study of TPO has prognostic
value, as well as that of Ki67 and p53. However, our re-
sults show that an initial analysis of TPO in cytology
samples is not effective to distinguish benign from ma-
lignant lesions because of TPO expression variability in
follicular tumors, consistent with other reports [23, 24].
Nevertheless, TPO may be useful, together with other
markers, in confirming or ruling out benign diseases ex-
cept for low-risk carcinomas such as MIFC.
The relationship between TPO expression and prog-
nosis of thyroid disease has been determined in different
studies. Weber, in his 1-year follow-up, observed that
100 % of patients with positive TPO and galectine-3 im-
munostaining were free of disease at the end of follow-
up, compared to 57 % of patients with a negative TPO
staining. It was suggested that the continued expression
of TPO in cancer might predict clinical outcome, rather
than the lack thereof [18]. Pulcrano et al. observed that
detectable TPO expression was associated with a lower
risk of metastasis in a 5-year follow-up, suggesting that
persistent functional differentiation reflects a less aggres-
sive behavior [25]. In the present study, overall survival
according to TPO expression showed that patients with
negative TPO had decreased survival rates, with a cumu-
lative overall survival of 20 years, but the comparison
between groups was not statistically significant (p =
0.34). In contrast, survival according to TNM stage was
statistically significant (p <0.001). Association between
disease-free survival and TPO expression was not sig-
nificant between groups; however, patients with negative
or weak TPO levels had a survival of 72 % and 86 %, re-
spectively, in contrast to the 20-year survival rate of
100 % seen with intense TPO expression.
Within the limitations of our study we must under-
score the indolent nature of differentiated thyroid cancer
and its low mortality rate. Therefore, assessing disease-
free survival is challenging since relapses are usually
asymptomatic. Nevertheless, this study has detected sig-
nificant differences in overall survival according to TNM
stage in association with TPO levels, and we believe this
is due to our sample size and follow-up length, which
reached a maximum of 20 years. Our results should be
interpreted cautiously since the study may be influenced
by a selection bias, as not all patients in the period
referred were included in the study. Lastly, the number
of thyroid malignancy samples analyzed is limited, espe-
cially when considering the subdivisions included in the
classification of thyroid tumors, which may be consid-
ered an additional limitation.
Conclusions
In our study, TPO levels represent a useful prognostic
factor for differentiated thyroid cancer. It may be highly
useful for patient follow-up. A pronounced TPO fall re-
quires assessment because of a high risk for local and/or
distant relapse and decreased survival. The difference in
TPO expression between MIFC and WIFC is an interest-
ing finding in this study, and should be considered. In
view of our results, TPO cannot be considered an effect-
ive diagnostic marker to separate benign from malignant
disease following fine-needle aspiration in cases of fol-
licular proliferation [18, 19]. Further prospective studies
are needed.
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